Overview

DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Status:
Withdrawn
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization. It is hypothesized that the combination of DLBS1033 with aspirin and clopidogrel will result in greater reduction of infarct size in comparison with that of aspirin and clopidogrel alone.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Dexa Medica Group